Detalhe da pesquisa
1.
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
N Engl J Med
; 381(25): 2403-2415, 2019 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562800
2.
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
Br J Clin Pharmacol
; 88(7): 3182-3192, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35029306
3.
A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer.
Invest New Drugs
; 39(6): 1613-1623, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34264412
4.
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
Gynecol Oncol
; 161(2): 512-515, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33610319
5.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 21(1): 105-120, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31753727
6.
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Invest New Drugs
; 38(4): 1145-1155, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31707688
7.
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
Gynecol Oncol
; 156(1): 13-22, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31708167
8.
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
Gynecol Oncol
; 156(1): 23-31, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31791552
9.
Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE).
BMC Urol
; 20(1): 181, 2020 Nov 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33160359
10.
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.
Genes Dev
; 25(23): 2465-79, 2011 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22156207
11.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
Lancet
; 390(10109): 2266-2277, 2017 Nov 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-28916371
12.
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Invest New Drugs
; 36(6): 1016-1025, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29611022
13.
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Gynecol Oncol
; 148(3): 507-514, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29352572
14.
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Lancet Oncol
; 18(1): 75-87, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27908594
15.
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Gynecol Oncol
; 147(2): 267-275, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28882436
16.
A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Int J Gynecol Cancer
; 26(2): 255-60, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26745694
17.
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 137(3): 386-91, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25818403
18.
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
J Clin Oncol
; 41(1): 107-116, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35867965
19.
Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients.
Commun Med (Lond)
; 3(1): 154, 2023 Oct 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37880389
20.
Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Gynecol Oncol
; 125(3): 621-4, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22446622